APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antithrombin (Recombinant)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antithrombin (Recombinant) Market Outlook and Growth Opportunities 2026

2 January 2026190 pages

Choose your research edition.

Industry ResearchAntithrombin (Recombinant) Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Antithrombin (Recombinant) Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Antithrombin (Recombinant) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antithrombin (Recombinant) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Antithrombin (Recombinant) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Antithrombin (Recombinant) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antithrombin (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antithrombin (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antithrombin (Recombinant) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antithrombin (Recombinant) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antithrombin (Recombinant) market include LFB Biotechnologies. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antithrombin (Recombinant) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antithrombin (Recombinant) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antithrombin (Recombinant) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antithrombin (Recombinant) market size, projected growth trends, production technologies, key applications, and end-use industries.

Antithrombin (Recombinant) Segment by Company

LFB Biotechnologies

Antithrombin (Recombinant) Segment by Type

Lyophilized Formulation

Lyophilized Powder

Antithrombin (Recombinant) Segment by Application

Hospital

Clinic

Antithrombin (Recombinant) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antithrombin (Recombinant) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antithrombin (Recombinant) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antithrombin (Recombinant) significant trends, drivers, influence factors in global and regions.

6. To analyze Antithrombin (Recombinant) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antithrombin (Recombinant) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antithrombin (Recombinant) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antithrombin (Recombinant).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antithrombin (Recombinant) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antithrombin (Recombinant) industry.

Chapter 3: Detailed analysis of Antithrombin (Recombinant) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antithrombin (Recombinant) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antithrombin (Recombinant) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antithrombin (Recombinant) Industry Trends Table 2. Antithrombin (Recombinant) Industry Drivers Table 3. Antithrombin (Recombinant) Industry Opportunities and Challenges Table 4. Antithrombin (Recombinant) Industry Restraints Table 5. Global Antithrombin (Recombinant) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antithrombin (Recombinant) Revenue Share by Company (2021-2026) Table 7. Global Antithrombin (Recombinant) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antithrombin (Recombinant) Sales Volume Share by Company (2021-2026) Table 9. Global Antithrombin (Recombinant) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antithrombin (Recombinant) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antithrombin (Recombinant) Key Company Manufacturing Base & Headquarters Table 12. Global Antithrombin (Recombinant) Company, Product Type & Application Table 13. Global Antithrombin (Recombinant) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antithrombin (Recombinant) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lyophilized Formulation Table 18. Significant Companies of Lyophilized Powder Table 19. Global Antithrombin (Recombinant) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antithrombin (Recombinant) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Antithrombin (Recombinant) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Antithrombin (Recombinant) Sales Volume Share by Type (2021-2026) Table 23. Global Antithrombin (Recombinant) Sales Volume Share by Type (2027-2032) Table 24. Global Antithrombin (Recombinant) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antithrombin (Recombinant) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antithrombin (Recombinant) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antithrombin (Recombinant) Sales Value Share by Type (2021-2026) Table 28. Global Antithrombin (Recombinant) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Antithrombin (Recombinant) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Antithrombin (Recombinant) Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Antithrombin (Recombinant) Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Antithrombin (Recombinant) Sales Volume Share by Application (2021-2026) Table 35. Global Antithrombin (Recombinant) Sales Volume Share by Application (2027-2032) Table 36. Global Antithrombin (Recombinant) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Antithrombin (Recombinant) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Antithrombin (Recombinant) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Antithrombin (Recombinant) Sales Value Share by Application (2021-2026) Table 40. Global Antithrombin (Recombinant) Sales Value Share by Application (2027-2032) Table 41. Global Antithrombin (Recombinant) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Antithrombin (Recombinant) Sales by Region (2021-2026) & (K Units) Table 43. Global Antithrombin (Recombinant) Sales Market Share by Region (2021-2026) Table 44. Global Antithrombin (Recombinant) Sales by Region (2027-2032) & (K Units) Table 45. Global Antithrombin (Recombinant) Sales Market Share by Region (2027-2032) Table 46. Global Antithrombin (Recombinant) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Antithrombin (Recombinant) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Antithrombin (Recombinant) Sales Value Share by Region (2021-2026) Table 49. Global Antithrombin (Recombinant) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Antithrombin (Recombinant) Sales Value Share by Region (2027-2032) Table 51. Global Antithrombin (Recombinant) Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Antithrombin (Recombinant) Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Antithrombin (Recombinant) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Antithrombin (Recombinant) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Antithrombin (Recombinant) Sales by Country (2021-2026) & (K Units) Table 56. Global Antithrombin (Recombinant) Sales Market Share by Country (2021-2026) Table 57. Global Antithrombin (Recombinant) Sales by Country (2027-2032) & (K Units) Table 58. Global Antithrombin (Recombinant) Sales Market Share by Country (2027-2032) Table 59. Global Antithrombin (Recombinant) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Antithrombin (Recombinant) Sales Value Market Share by Country (2021-2026) Table 61. Global Antithrombin (Recombinant) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Antithrombin (Recombinant) Sales Value Market Share by Country (2027-2032) Table 63. LFB Biotechnologies Company Information Table 64. LFB Biotechnologies Business Overview Table 65. LFB Biotechnologies Antithrombin (Recombinant) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. LFB Biotechnologies Antithrombin (Recombinant) Product Portfolio Table 67. LFB Biotechnologies Recent Development Table 68. Key Raw Materials Table 69. Raw Materials Key Suppliers Table 70. Antithrombin (Recombinant) Distributors List Table 71. Antithrombin (Recombinant) Customers List Table 72. Research Programs/Design for This Report Table 73. Authors List of This Report Table 74. Secondary Sources Table 75. Primary Sources List of Figures Figure 1. Antithrombin (Recombinant) Product Image Figure 2. Global Antithrombin (Recombinant) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antithrombin (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antithrombin (Recombinant) Sales (2021-2032) & (K Units) Figure 5. Global Antithrombin (Recombinant) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antithrombin (Recombinant) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lyophilized Formulation Image Figure 10. Lyophilized Powder Image Figure 11. Global Antithrombin (Recombinant) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antithrombin (Recombinant) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antithrombin (Recombinant) Sales Volume Share by Type (2021-2032) Figure 14. Global Antithrombin (Recombinant) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antithrombin (Recombinant) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antithrombin (Recombinant) Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Antithrombin (Recombinant) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Antithrombin (Recombinant) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Antithrombin (Recombinant) Sales Volume Share by Application (2021-2032) Figure 22. Global Antithrombin (Recombinant) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Antithrombin (Recombinant) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Antithrombin (Recombinant) Sales Value Share by Application (2021-2032) Figure 25. Global Antithrombin (Recombinant) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Antithrombin (Recombinant) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Antithrombin (Recombinant) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Antithrombin (Recombinant) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Antithrombin (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 30. North America Antithrombin (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Antithrombin (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Antithrombin (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Antithrombin (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Antithrombin (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Antithrombin (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 36. South America Antithrombin (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Antithrombin (Recombinant) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Antithrombin (Recombinant) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Antithrombin (Recombinant) Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Antithrombin (Recombinant) Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Lyophilized Formulation
  • Lyophilized Powder
Applications
  • Hospital
  • Clinic
Companies covered
  • LFB Biotechnologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antithrombin (Recombinant) Sales Value (2021-2032)
  4. 1.2.2 Global Antithrombin (Recombinant) Sales Volume (2021-2032)
  5. 1.2.3 Global Antithrombin (Recombinant) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antithrombin (Recombinant) Market Dynamics
  1. 2.1 Antithrombin (Recombinant) Industry Trends
  2. 2.2 Antithrombin (Recombinant) Industry Drivers
  3. 2.3 Antithrombin (Recombinant) Industry Opportunities and Challenges
  4. 2.4 Antithrombin (Recombinant) Industry Restraints
3 Antithrombin (Recombinant) Market by Company
  1. 3.1 Global Antithrombin (Recombinant) Company Revenue Ranking in 2025
  2. 3.2 Global Antithrombin (Recombinant) Revenue by Company (2021-2026)
  3. 3.3 Global Antithrombin (Recombinant) Sales Volume by Company (2021-2026)
  4. 3.4 Global Antithrombin (Recombinant) Average Price by Company (2021-2026)
  5. 3.5 Global Antithrombin (Recombinant) Company Ranking (2024-2026)
  6. 3.6 Global Antithrombin (Recombinant) Company Manufacturing Base and Headquarters
  7. 3.7 Global Antithrombin (Recombinant) Company Product Type and Application
  8. 3.8 Global Antithrombin (Recombinant) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antithrombin (Recombinant) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antithrombin (Recombinant) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antithrombin (Recombinant) Market by Type
  1. 4.1 Antithrombin (Recombinant) Type Introduction
  2. 4.1.1 Lyophilized Formulation
  3. 4.1.2 Lyophilized Powder
  4. 4.2 Global Antithrombin (Recombinant) Sales Volume by Type
  5. 4.2.1 Global Antithrombin (Recombinant) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antithrombin (Recombinant) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antithrombin (Recombinant) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antithrombin (Recombinant) Sales Value by Type
  9. 4.3.1 Global Antithrombin (Recombinant) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antithrombin (Recombinant) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antithrombin (Recombinant) Sales Value Share by Type (2021-2032)
5 Antithrombin (Recombinant) Market by Application
  1. 5.1 Antithrombin (Recombinant) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Antithrombin (Recombinant) Sales Volume by Application
  5. 5.2.1 Global Antithrombin (Recombinant) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antithrombin (Recombinant) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Antithrombin (Recombinant) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Antithrombin (Recombinant) Sales Value by Application
  9. 5.3.1 Global Antithrombin (Recombinant) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antithrombin (Recombinant) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Antithrombin (Recombinant) Sales Value Share by Application (2021-2032)
6 Antithrombin (Recombinant) Regional Sales and Value Analysis
  1. 6.1 Global Antithrombin (Recombinant) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antithrombin (Recombinant) Sales by Region (2021-2032)
  3. 6.2.1 Global Antithrombin (Recombinant) Sales by Region: 2021-2026
  4. 6.2.2 Global Antithrombin (Recombinant) Sales by Region (2027-2032)
  5. 6.3 Global Antithrombin (Recombinant) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antithrombin (Recombinant) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antithrombin (Recombinant) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antithrombin (Recombinant) Sales Value by Region (2027-2032)
  9. 6.5 Global Antithrombin (Recombinant) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antithrombin (Recombinant) Sales Value (2021-2032)
  12. 6.6.2 North America Antithrombin (Recombinant) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antithrombin (Recombinant) Sales Value (2021-2032)
  15. 6.7.2 Europe Antithrombin (Recombinant) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antithrombin (Recombinant) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antithrombin (Recombinant) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antithrombin (Recombinant) Sales Value (2021-2032)
  21. 6.9.2 South America Antithrombin (Recombinant) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antithrombin (Recombinant) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antithrombin (Recombinant) Sales Value Share by Country, 2025 VS 2032
7 Antithrombin (Recombinant) Country-level Sales and Value Analysis
  1. 7.1 Global Antithrombin (Recombinant) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antithrombin (Recombinant) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antithrombin (Recombinant) Sales by Country (2021-2032)
  4. 7.3.1 Global Antithrombin (Recombinant) Sales by Country (2021-2026)
  5. 7.3.2 Global Antithrombin (Recombinant) Sales by Country (2027-2032)
  6. 7.4 Global Antithrombin (Recombinant) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antithrombin (Recombinant) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antithrombin (Recombinant) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antithrombin (Recombinant) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antithrombin (Recombinant) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antithrombin (Recombinant) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 LFB Biotechnologies
  2. 8.1.1 LFB Biotechnologies Company Information
  3. 8.1.2 LFB Biotechnologies Business Overview
  4. 8.1.3 LFB Biotechnologies Antithrombin (Recombinant) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 LFB Biotechnologies Antithrombin (Recombinant) Product Portfolio
  6. 8.1.5 LFB Biotechnologies Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antithrombin (Recombinant) Value Chain Analysis
  2. 9.1.1 Antithrombin (Recombinant) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antithrombin (Recombinant) Sales Mode & Process
  6. 9.2 Antithrombin (Recombinant) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antithrombin (Recombinant) Distributors
  9. 9.2.3 Antithrombin (Recombinant) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst